midodrine has been researched along with Body Weight in 2 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adding rifaximin and midodrine to DT enhanced diuresis in refractory ascites with improved systemic, renal hemodynamics and short-term survival." | 9.22 | Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. ( Hanafy, AS; Hassaneen, AM, 2016) |
| "Midodrine treatment also significantly increased postdialysis systolic and diastolic blood pressures from baseline values of 90." | 6.68 | Midodrine for the treatment of intradialytic hypotension. ( Li, HP; Lim, PS; Lim, YT; Yang, CC; Yeh, CH, 1997) |
| "Adding rifaximin and midodrine to DT enhanced diuresis in refractory ascites with improved systemic, renal hemodynamics and short-term survival." | 5.22 | Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. ( Hanafy, AS; Hassaneen, AM, 2016) |
| "Midodrine treatment also significantly increased postdialysis systolic and diastolic blood pressures from baseline values of 90." | 2.68 | Midodrine for the treatment of intradialytic hypotension. ( Li, HP; Lim, PS; Lim, YT; Yang, CC; Yeh, CH, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanafy, AS | 1 |
| Hassaneen, AM | 1 |
| Lim, PS | 1 |
| Yang, CC | 1 |
| Li, HP | 1 |
| Lim, YT | 1 |
| Yeh, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children: a Pilot Study[NCT04043858] | 20 participants (Anticipated) | Interventional | 2020-06-05 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for midodrine and Body Weight
| Article | Year |
|---|---|
Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.
Topics: Aldosterone; Anti-Infective Agents; Ascites; Blood Pressure; Body Weight; Diuretics; Drug Therapy, C | 2016 |
Midodrine for the treatment of intradialytic hypotension.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Body Weight; Female; H | 1997 |